4 completed. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
| Phase 2 | 1 | Completed 1 |
Follow OSA: new trials by email Literature Review of OSA trials Research Report on OSA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight Orforglipron, Placebo - OSA, Overweight or Obesity | Phase 3 | Completed | Eli Lilly and Company | 712 | 2024-10-22 | 2026-09-14 |
| Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study) AD109, Placebo - OSA | Phase 3 | Completed | Apnimed | 646 | 2023-09-16 | 2026-09-11 |
| Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo) AD109, Placebo - OSA | Phase 3 | Completed | Apnimed | 660 | 2023-08-28 | 2026-11-03 |
| Validation of the AVAPS AE Algorithm in Chronic Obstructive Pulmonary Disease (COPD) Patients AVAPS-AE, Usual care - COPD, OSA | Phase 2 / Phase 3 | Completed | Patrick Murphy | 10 | 2012-05-01 | 2016-08-18 |
Sleep Apnea, Obstructive (2) · Obesity (1) · Overweight (1) · Pulmonary Disease, Chronic Obstructive (1) · Respiratory Insufficiency (1)
Respiration Disorders (3) · Respiratory Tract Diseases (3) · Apnea (2) · Dyssomnias (2) · Nervous System Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Sleep Apnea Syndromes (2) · Sleep Disorders, Intrinsic (2) · Sleep Wake Disorders (2) · Body Weight (1) · Chronic Disease (1) · Disease Attributes (1) · Lung Diseases (1) · Lung Diseases, Obstructive (1) · Nutrition Disorders (1)
orforglipron (1)
Apnimed (2) · Eli Lilly and Company (1) · Patrick Murphy (1)
United States (3) · Argentina (1) · Brazil (1) · Canada (1) · China (1) · Czechia (1) · Germany (1) · Japan (1) · Mexico (1) · Taiwan (1) · United Kingdom (1)
Nicholas Hart (1)